Sumary of Most patients with allergic reactions to first COVID-19 vaccine receive second dose safely:
- Back to Healio Although the CDC lists a severe or immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine as a contraindication for the second dose, a study found most individuals with a dose one reaction received dose two safely.
- However, the results, published in The Journal of Allergy and Clinical Immunology: In Practice, also showed a limited role for excipient skin testing among patients with a reaction to the first dose.
- 2021.06.010. The Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines include polyethylene glycol 2000 (PEG-2000), which has been examined as a possible cause of allergic reactions, though supportive evidence has been limited, Anna R.
- Meanwhile, the Janssen adenovirus vector vaccine includes polysorbate 80. The researchers aimed to discover if there is a relationship between allergies to these excipients and allergic reactions to the vaccines.
- They also evaluated the outcomes associated with excipient skin testing following allergic reactions to the first dose of the vaccine.
- Out of 38,933 Moderna doses and 25,906 Pfizer-BioNTech doses administered between Jan.
- 6 and March 3, 2021 at Mass General Brigham (MGB), the analysis included 80 patients (89% women;
- Researchers assessed these patients using a risk stratification algorithm, which uses a clinical history with excipient skin testing to evaluate higher risk individuals.